Anti-tuberculosis treatment strategies and drug development: challenges and priorities

Véronique A. Dartois,Eric J. Rubin
DOI: https://doi.org/10.1038/s41579-022-00731-y
IF: 88.1
2022-04-28
Nature Reviews Microbiology
Abstract:Nature Reviews Microbiology, Published online: 27 April 2022; doi:10.1038/s41579-022-00731-y The anti-tuberculosis drug candidate pipeline is promising, but the recent breakthroughs are challenged with the need to prioritize drug combinations for clinical trials and revamping trial designs to accelerate regimen development. In this Review, Dartois and Rubin explore treatment challenges, drug development priorities, and approaches — from basic research to preclinical evaluation — that lead to the selection of drug combinations earlier in the discovery cascade to accelerate the approval of shorter treatment regimens.
microbiology
What problem does this paper attempt to address?